Latest news for Puradelta Lestari (OTC:PTPLF) Stock

PT Puradelta Lestari tbk is a property development company operating in Indonesia. The company develops residential, commercial, and industrial real estate. Many of its projects have a foothold in Eastern Jakarta. Its business segment includes Industrial, residential, rental, Commercial, Financing component and hotel. The industrial segment derives maximum revenue.

PT PURADELTA LESTARI TBK by PT PURADELTA LESTARI TBK

PT Puradelta Lestari tbk

News

Guidance

QTWO

Q2 Holdings Expects Total Non-GAAP Revenue Of $171.5M - $174.5M For Q3 ($172.74M); Revises FY24 Range From $686M - $692M To $688.5M - $692.5M (Est $689.70M)

Third Quarter&nbsp;2024
<ul>
<li>Increasing revenue&nbsp;guidance&nbsp;to a range of&nbsp;$237.2 million&nbsp;to&nbsp;$241.2 million, up&nbsp;$9.2 million&nbsp;at the midpoint from the prior&nbsp;guidance&nbsp;of&nbsp;$230 million. The revised&nbsp;guidance&nbsp;represents a year-over-year increase of&nbsp;26%&nbsp;to&nbsp;28%.</li>
<li>Increasing Adjusted EBITDA&nbsp;guidance&nbsp;to a range of&nbsp;$46.8 million&nbsp;to&nbsp;$47.3 million, up&nbsp;$1.8 million&nbsp;at the midpoint from the prior&nbsp;guidance&nbsp;of&nbsp;$45.3 million. The revised&nbsp;guidance&nbsp;represents a year-over-year increase of&nbsp;39%&nbsp;to&nbsp;40%&nbsp;and an Adjusted EBITDA margin of&nbsp;19.4%&nbsp;to&nbsp;19.9%.</li>
</ul>

ZETA

Zeta Now Sees Q3 Revenue Of $237.2M - $241.2M, Est $230.43M

Compass Diversified Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.50 by 6 percent. The company reported quarterly sales of $542.595 million which missed the analyst consensus estimate of $550.120 million by 1.37 percent. This is a 3.52 percent increase over sales of $524.159 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CODI

Compass Diversified Hldgs Q2 2024 Adj. EPS $0.53 Beats $0.50 Estimate, Sales $542.595M Miss $550.120M Estimate

Full Year 2024
<ul>
<li>Increasing revenue&nbsp;guidance&nbsp;to a range of&nbsp;$920 million&nbsp;to&nbsp;$930 million, up&nbsp;$25 million&nbsp;at the midpoint from the prior&nbsp;guidance&nbsp;$900 million. Revised&nbsp;guidance&nbsp;represents a year-over-year increase of&nbsp;26%&nbsp;to&nbsp;28%.</li>
<li>Increasing Adjusted EBITDA&nbsp;guidance&nbsp;to a range of&nbsp;$174.5 million&nbsp;to&nbsp;$176.5 million, up&nbsp;$4.5 million&nbsp;at the midpoint from the prior&nbsp;guidance&nbsp;of&nbsp;$171 million. Revised&nbsp;guidance&nbsp;represents a year-over-year increase of&nbsp;35%&nbsp;to&nbsp;36%&nbsp;and an Adjusted EBITDA margin of&nbsp;18.8%&nbsp;to&nbsp;19.2%.</li>
<li>Increasing Free Cash Flow&nbsp;guidance&nbsp;to a range of&nbsp;$80 million&nbsp;to&nbsp;$90 million, up&nbsp;$5 million&nbsp;at the midpoint from the prior&nbsp;guidance&nbsp;of&nbsp;$80 million.</li>
</ul>

Zeta Raises 2024 Revenue Guidance From $895M - $905M To $920M - $930M, Est $900.45M

Gran Tierra Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GTE#AMEX">GTE</a>) reported quarterly earnings of $1.16 per share. The company reported $165.609 million in sales this quarter. This is a 4.88 percent increase over sales of $157.902 million the same period last year.

Gran Tierra Energy Q2 2024 GAAP EPS $1.16, Sales $165.609M Up From $157.902M YoY

Star Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGU#NYSE">SGU</a>) reported quarterly losses of $(0.31) per share. This is a 53.73 percent increase over losses of $(0.67) per share from the same period last year. The company reported $331.64 million in sales this quarter. This is a 10.50 percent increase over sales of $300.12 million the same period last year.

Star Group Q3 EPS $(0.31) Up From $(0.67) YoY, Sales $331.64M Up From $300.12M YoY

Munipalli is leaving for family reasons, and will oversee an orderly transition, remaining with the company through September 30, 2024.

Management

RELY

Remitly Appoints Vikas Mehta As CFO, Succeeding Hemanth Munipalli, Effective August 19, 2024

RSI expects revenue for the full year ending December 31, 2024 to be between&nbsp;$860&nbsp;and&nbsp;$900 million, increasing the midpoint by&nbsp;$45 million&nbsp;compared to the prior&nbsp;guidance. At the midpoint of the range, revenue of&nbsp;$880 million&nbsp;represents&nbsp;27%&nbsp;year-over-year growth when compared to&nbsp;$691 million&nbsp;of revenue for 2023.
RSI expects Adjusted EBITDA&nbsp;for the full year ending December 31, 2024 to be between&nbsp;$64&nbsp;and&nbsp;$72 million, increasing the midpoint by&nbsp;$13 million&nbsp;compared to the prior&nbsp;guidance. At the midpoint of the range, Adjusted EBITDA of&nbsp;$68 million&nbsp;compares to&nbsp;$8.2 million&nbsp;of Adjusted EBITDA for 2023.

Rush Street Interactive Raises FY24 Revenue Outlook From $810M - $860M To $860M - $900M, Est $845.67M

PGRE

Paramount Group Narrows Estimated FY24 Core FFO Guidance From $0.75 - $0.81 To $0.76 - $0.80; Est $0.77

New York Mortgage Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMT#NASDAQ">NYMT</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $0.01 by 3000 percent. The company reported quarterly sales of $19.044 million which missed the analyst consensus estimate of $23.479 million by 18.89 percent. This is a 25.82 percent increase over sales of $15.136 million the same period last year.

NYMT

New York Mortgage Trust Q2 2024 GAAP EPS $(0.29) Misses $0.01 Estimate, Sales $19.044M Miss $23.479M Estimate

The Company is narrowing its previous&nbsp;guidance&nbsp;for the year ending December 31, 2024 primarily to reflect the impact of its recent&nbsp;$400 million&nbsp;bond issuance as follows:

Piedmont Office Realty Trust Revises FY24 Core FFO Outlook From $1.46 - $1.56 To $1.46 - $1.52, Est $1.50

Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $66.909 million which beat the analyst consensus estimate of $65.784 million by 1.71 percent. This is a 35.59 percent increase over sales of $49.346 million the same period last year.

EOLS

Evolus Q2 2024 Adj. EPS $(0.04) Beats $(0.05) Estimate, Sales $66.909M Beat $65.784M Estimate

The arbitration merits hearing about the applicability of the Stabroek ROFR to the Merger has been scheduled for May 2025, with a decision expected in the following three months. Hess and Chevron had expected and requested that this hearing be held earlier, but the arbitrators&rsquo; common schedules did not make this possible.
The views of Hess and Chevron on the merits remain unchanged. Exxon and CNOOC continue to ignore the plain language of the operating agreement, and Hess and Chevron remain confident that the arbitration will confirm that the Stabroek ROFR does not apply to the Merger.
Hess and Chevron remain committed to the Merger and look forward to combining the two companies.

Hess Says Arbitration Merits Hearing About Applicability Of Stabroek ROFR To Merger Scheduled For May 2025; Hess And Chevron Had Expected, Requested That This Hearing Be Held Earlier - Filing

Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.02) by 950 percent. This is a 440 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $237.059 million which missed the analyst consensus estimate of $242.604 million by 2.29 percent. This is a 11.15 percent decrease over sales of $266.814 million the same period last year.

Stoneridge Q2 2024 Adj. EPS $0.17 Beats $(0.02) Estimate, Sales $237.059M Miss $242.604M Estimate

Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.10 by 30 percent. This is a 160 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $227.839 million which beat the analyst consensus estimate of $212.446 million by 7.25 percent. This is a 32.61 percent increase over sales of $171.817 million the same period last year.

Zeta Global Holdings Q2 2024 Adj. EPS $0.13 Beats $0.10 Estimate, Sales $227.839M Beat $212.446M Estimate

CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) reported quarterly losses of $(0.07) per share. This is a 275 percent decrease over earnings of $0.04 per share from the same period last year. The company reported $5.03 million in sales this quarter. This is a 32.19 percent decrease over sales of $7.42 million the same period last year.

CPSH

CPS Technologies Q2 GAAP EPS $(0.07) Down From $0.04 YoY, Sales $5.03M Down From $7.42M YoY

Alamos Gold Says Remain Well Positioned To Achieve Full Year Guidance, And Deliver Significant Production Growth, At Declining Costs Over Next Several Years

Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/07/b40080650/exact-sciences-announces-second-quarter-2024-results">details from the report. </a>
The Details: Exact Sciences reported quarterly losses of 9 cents per share, which beat the analyst consensus estimate of losses of 32 cents by 71.88%.
The company reported quarterly sales of $699.264 million which beat the analyst consensus estimate of $690.003 million and is a 12.41% increase over sales from the same period last year. Screening revenue was $532 million, a 15% increase, and Precision Oncology revenue was $168 million, an increase of 6%.
Exact Science says it screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX. 
The company also announced an exclusive <a href="https://www.benzinga.com/pressreleases/24/07/n40080659/twinstrand-biosciences-and-exact-sciences-announce-exclusive-license-agreement-for-duplex-sequenci">licensing agreement</a> with TwinStrand Biosciences for its patent estate in the cell free nucleic acid sequencing space.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/07/40076709/whats-going-on-with-sofi-stock-after-earnings">What&#8217;s Going On With SoFi Stock After Earnings?</a>
&#8220;Our second quarter results show the dedication of Exact Sciences&#8217; world-class team and the power of our unique platform,&#8221; said Kevin Conroy, chairman and CEO. &#8220;We delivered answers to more patients and healthcare professionals than ever before, achieved record revenue and profitability, and advanced each of our key pipeline programs. Momentum continues to build, fueling our purpose to help eradicate cancer.&#8221;
Outlook: Exact Sciences maintained its full-year revenue guidance of between $2.81 billion and $2.85 billion, versus the $2.829 estimate.
EXAS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Exact Sciences shares are up 9.46% after-hours at $50.00 at the time of publication Wednesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40051630/match-group-stock-climbs-on-strong-q2-results-hinge-revenue-up-48">Match Group Stock Climbs On Strong Q2 Results, Hinge Revenue Up 48%</a></li>
</ul>
Image: Courtesy of Exact Sciences Corporation

Biotech

Health Care

After-Hours Center

Movers

EXAS

Exact Sciences Stock Climbs After Strong Q2 Results

Sun Communities Reiterates FY24 Core FFO Per Share Guidance Of $7.06 - $7.22, Est $7.12

Sturm Ruger &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGR#NYSE">RGR</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.76 by 38.16 percent. This is a 48.35 percent decrease over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $130.761 million which missed the analyst consensus estimate of $137.601 million by 4.97 percent. This is a 8.43 percent decrease over sales of $142.804 million the same period last year.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Puradelta Lestari

News

Latest news for Puradelta Lestari (OTC:PTPLF) Stock